These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

288 related articles for article (PubMed ID: 5523796)

  • 21. [The treatment of Parkinson's disease with L-dopa].
    Dalle Ore G; Bricolo A; Robotti E; Bazzan A; Mazza C
    Policlinico Prat; 1970 Apr; 77(16):509-24. PubMed ID: 5443873
    [No Abstract]   [Full Text] [Related]  

  • 22. [L-dopa in the treatment of Parkinson's disease. Preliminary report].
    Poch GF
    Prensa Med Argent; 1969 Oct; 56(34):1629-32. PubMed ID: 5405572
    [No Abstract]   [Full Text] [Related]  

  • 23. Levodopa and physical therapy in treatment of patients with Parkinson's disease.
    Stern PH; McDowell F; Miller JM; Robinson M
    Arch Phys Med Rehabil; 1970 May; 51(5):273-7. PubMed ID: 5420013
    [No Abstract]   [Full Text] [Related]  

  • 24. [Action of L-dopa in Parkinson's syndrome].
    Ucar S; Eiras J
    Rev Clin Esp; 1971 Feb; 120(3):257-62. PubMed ID: 5568474
    [No Abstract]   [Full Text] [Related]  

  • 25. Double-blind, placebo-controlled study of levodopa therapy in Parkinson's disease.
    Muenter MD
    Neurology; 1970 Dec; 20(12):6-13. PubMed ID: 4924343
    [No Abstract]   [Full Text] [Related]  

  • 26. Fourteen-year final report of the randomized PDRG-UK trial comparing three initial treatments in PD.
    Katzenschlager R; Head J; Schrag A; Ben-Shlomo Y; Evans A; Lees AJ;
    Neurology; 2008 Aug; 71(7):474-80. PubMed ID: 18579806
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [L-dopa in Parkinson's syndrome].
    Filho RM; de Karam GM
    Rev Bras Med; 1971 May; 28(5):220-31. PubMed ID: 5563096
    [No Abstract]   [Full Text] [Related]  

  • 28. [Personal experience in the treatment of Parkinson's disease with L-Dopa].
    Figuerido JA; De la Herrán J
    Rev Clin Esp; 1970 Dec; 119(6):555-62. PubMed ID: 5509794
    [No Abstract]   [Full Text] [Related]  

  • 29. [Our first observations on Parkinson's disease or parkinsonian syndromes treated with L-dopa].
    Boudouresques J; Khalil R; Vigouroux RA; Gosset A; Daniel F; Dufour H
    Mars Med; 1971; 108(2):85-9. PubMed ID: 5548385
    [No Abstract]   [Full Text] [Related]  

  • 30. [Silent period in patients with Parkinson's disease treated with L-Dopa].
    Palao Sánchez A
    Arch Neurobiol (Madr); 1973; 36(1):47-56. PubMed ID: 4706780
    [No Abstract]   [Full Text] [Related]  

  • 31. L-dopa in Parkinson's disease. A report on 95 cases and review of the literature.
    Lewis I
    J Med Assoc State Ala; 1971 May; 40(11):709-18. PubMed ID: 5573008
    [No Abstract]   [Full Text] [Related]  

  • 32. Parkinson's disease: L-dopa treatment and handwriting area.
    Knopp W; Paulson G; Allen JN; Smeltzer D; Brown FD; Kose W
    Curr Ther Res Clin Exp; 1970 Mar; 12(3):115-25. PubMed ID: 4985489
    [No Abstract]   [Full Text] [Related]  

  • 33. Evaluation of terguride in patients with Parkinson's disease.
    Suchy I; Rinne UK; Wachtel H
    Adv Neurol; 1987; 45():577-81. PubMed ID: 3548267
    [No Abstract]   [Full Text] [Related]  

  • 34. [Treatment of Parkinson's syndrome with L-dopa].
    Ljung O
    Lakartidningen; 1972 Jun; 69(24):2940-4. PubMed ID: 5037135
    [No Abstract]   [Full Text] [Related]  

  • 35. [Preliminary impressions of the therapeutic effectiveness of L-dopa in Parkinson's disease].
    Buscaino GA; Campanella G
    Sist Nerv; 1970; 22(2):82-91. PubMed ID: 5504561
    [No Abstract]   [Full Text] [Related]  

  • 36. Abnormal excitability of premotor-motor connections in de novo Parkinson's disease.
    Buhmann C; Gorsler A; Bäumer T; Hidding U; Demiralay C; Hinkelmann K; Weiller C; Siebner HR; Münchau A
    Brain; 2004 Dec; 127(Pt 12):2732-46. PubMed ID: 15509619
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Pharmacodynamics of 3, 4-dihydroxyphenylalanine (Dopa) in Parkinson's disease.
    Van Woert MH
    Conn Med; 1970 Jun; 34(6):401-5. PubMed ID: 5431103
    [No Abstract]   [Full Text] [Related]  

  • 38. Some quantitative behavioural changes in L-dopa therapy.
    Meier MJ; Baker AB; Martin WE
    Trans Am Neurol Assoc; 1970; 95():64-8. PubMed ID: 5514413
    [No Abstract]   [Full Text] [Related]  

  • 39. L-dopa therapy and intense individual care help Parkinson patients gain function and control.
    Strohfus S
    Mod Nurs Home; 1970 Jul; 25(1):37-40. PubMed ID: 5200670
    [No Abstract]   [Full Text] [Related]  

  • 40. Cerebrospinal fluid N-acetyl neuraminic acid in Parkinson's disease, before and after L-dopa therapy.
    Lipman IJ; Papadopoulos NM
    Dis Nerv Syst; 1973 Jan; 34(1):59-62. PubMed ID: 4709194
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.